NFE2L2 and chronic myelogenous leukemia, BCR-ABL1 positive: Inhibition of the Nrf2-TrxR Axis Sensitizes the Drug-Resistant Chronic Myelogenous Leukemia Cell Line K562/G01 to Imatinib Treatments